Linnaeus Therapeutics is focused on developing small molecule agents for cancer treatment, leveraging insights from clinical experiences to identify new therapeutic targets. Their lead compound, LNS8801, is a potent and specific agonist of the G protein-coupled estrogen receptor (GPER). This compound has shown promising results in preclinical models, demonstrating significant antitumor activity across various cancer types. Notably, LNS8801 not only acts effectively as a monotherapy but also exhibits enhanced effects when used in combination with established immunotherapies, indicating its potential to improve treatment outcomes for patients with advanced cancers.

The company’s approach is rooted in understanding the mechanisms behind the protective effects associated with female sex hormone signaling, particularly in relation to cancer incidence and survival rates. By investigating these mechanisms, Linnaeus aims to uncover new therapeutic targets that could lead to transformative cancer therapies. Clinical data presented at major oncology meetings, such as the European Society of Medical Oncology (ESMO) Annual Meeting, highlight the drug's ability to engage its target and correlate with clinical benefits, further supporting its development as a promising candidate in the oncology landscape.

United States

Linnaeus Therapeutics, Inc. is a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cancer therapies. The company was founded in 2016 and is based upon discoveries from the Ridky lab at the University of Pennsylvania. Linnaeus Therapeutics has been granted Orphan Drug Designation for LNS8801 for the treatment of patients with metastatic cutaneous melanoma.

Linnaeus Therapeutics

Company Details